Clinical trials: Schizophrenia and Related Disorders
Serious Mental Illness, Schizophrenia
Mindfulness-Based Therapy for Serious Mental Illness
Serious mental illness (SMI), encompassing schizophrenia-spectrum and major mood disorders, has been estimated to affect approximately 5.4% of the U.S. adult population each year.
- Conditions
- Serious Mental Illness, Schizophrenia, Major Depressive Disorder, Bipolar Disorder
- Trial name
- MBT (NCT06880796)
- Testing
- Mindfulness-based therapy, Treatment as Usual (TAU)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Butler Hospital
Epilepsy With Partial Onset Seizures With or Without Secondary Generalization, Psychoses
Epileptic Psychoses and Their Link With Ictal Emotions and Consciousness
Background : Psychiatric comorbidities are common in epilepsy, affecting 50 to 70% of patients, especially when the epilepsy is focal and drug-resistant.
- Conditions
- Epilepsy With Partial Onset Seizures With or Without Secondary Generalization, Psychoses, Epilepsy, Generalized
- Trial name
- ASPAIC (NCT06960811)
- Where
- France
- Volunteers
- 117 people
- Sponsor
- Central Hospital, Nancy, France
Schizophrenia, Bipolar Disorder
Evaluation of the In SHAPE Fitness Intervention for Adults With Serious Mental Illness
Few studies targeting obesity in serious mental illness have reported clinically significant risk reduction, and non have been replicated in community settings or demonstrated sustained outcomes after intervention withdrawal.
- Conditions
- Schizophrenia, Bipolar Disorder, Schizoaffective Disorder, Major Depressive Disorder
- Trial name
- NCT02334228
- Testing
- In SHAPE Lifestyles, Health Club Membership and Education
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Bipolar Disorder
Approaches For ThE pRioritization of Patients in priMAry Care Post-COVID To Reduce Health Inequities (AFTERMATH)
The COVID-19 pandemic significantly impacted primary care across Canada. Inequities in prevention activities and chronic disease management likely increased but the extent is unknown.
- Trial name
- AFTERMATH (NCT05823805)
- Testing
- Community Health Worker
- Volunteers
- 520 people
- Sponsor
- Unity Health Toronto
Schizophrenia, Bipolar Disorder
A Biological Signature for the Early Differential Diagnosis of Psychosis
Schizophrenia (SZ) and mood disorders (BD, MDD) are among the most disabling disorders worldwide, with a relevant social, functional, and economic burden.
- Conditions
- Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT06515522
- Testing
- differential diagnosis
- Volunteers
- 1,850 people
- Sponsor
- IRCCS San Raffaele
Sleep Initiation and Maintenance Disorders
A Double-blind, Group-comparison P-III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients
A multicenter, randomized, double-blind, triple-dummy, group-comparison study using placebo and nitrazepam as a comparative drug.
- Trial name
- NCT00374777
- Testing
- zolpidem MR, nitrazepam
- Where
- 6 sites in Japan
- Volunteers
- 450 people
- Sponsor
- Astellas Pharma Inc
Schizophrenia, Schizoaffective Disorder
Feasibility Electrical Stimulation Study for Visual Hallucinations
The visual system has increasingly been recognized as an important site of injury in patients with schizophrenia and other psychoses.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT04870710
- Testing
- transcranial electrical stimulation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Beth Israel Deaconess Medical Center
Bipolar Disorder, Schizophrenia
A Non-interventional Naturalistic Project to Investigate the Effect of the Use of SMS Text Service on Treatment Adherence in Patients Treated With Seroquel® (Quetiapine)
The basic hypothesis of this trial is that forgetfulness and failure to establish a routine that facilitates medication adherence are prominent reasons for non-adherence.
- Trial name
- SEQUEL (NCT00533260)
- Where
- 35 sites in Netherlands
- Volunteers
- 128 people
- Sponsor
- AstraZeneca
Acute Psychotic Episode, Schizophrenia Spectrum and Other Psychotic Disorders
Copeptin in Outcome Prediction of an Acute Psychotic Episode
An acute psychotic episode is a severe psychiatric syndrome which might occur in different psychiatric diagnoses. The outcome prediction of relapse rate of a psychotic episode within a certain time frame is difficult and depends…
- Conditions
- Acute Psychotic Episode, Schizophrenia Spectrum and Other Psychotic Disorders, Affective Disorder, Bipolar Disorder
- Trial name
- CoPsych (NCT03235908)
- Testing
- Observation only
- Where
- Switzerland
- Volunteers
- 73 people
- Sponsor
- University Hospital, Basel, Switzerland
Schizophrenia, Bipolar Disorder
Bio-equivalence Study Between SAPHRIS and Asenapine
This is a Multiple-dose, steady state, three-way reference-replicated crossover study. The purpose of this Study is to determine the bio-equivalence between SAPHRIS and Asenapine 10mg sublingual tablets.
- Trial name
- ASN (NCT01948024)
- Testing
- SAPHRIS, Asenapine
- Where
- 7 sites in United States
- Volunteers
- 65 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Alzheimer Disease
Home-based Transcranial Direct Current Stimulation (tDCS) for Behavioral Symptoms in Alzheimer's Disease and Related Dementias (ADRD)
The purpose of this study is to assess acceptability, and safety of providing tDCS to ADRD patients with behavioral symptoms and to assess the efficacy of tDCS for ADRD-related symptoms, mainly behavioral symptoms.
- Trial name
- NCT05478681
- Testing
- active tDCS
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- The University of Texas Health Science Center, Houston
Schizophrenia, Schizoaffective Disorder
Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome
The objective of this study is to determine the effect of various mood stabilizers (MS) on the insulin resistance syndrome (IRS; also called the metabolic syndrome) alone and in patients treated with antipsychotic drugs (APDs).
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT00288366
- Testing
- ziprasidone vs. aripiprazole, aripiprazole vs. ziprasidone
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Northwestern University
Schizophrenia, Bipolar Disorder
Integrated Care Including Assertive Community Treatment in Early Psychosis
Improvement of clinical long-term outcome through the implementation of early detection and intervention within a specialized network of integrated care (ACT and hometreatment) for adolescents and young adults with a first…
- Trial name
- ICEP (NCT02037581)
- Testing
- Early detection and Integrated Care, Standard Care
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Bipolar Disorder, Mania
Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women?
OBJECTIVE: To test the use of two adjunctive hormonal agents in a 28 day three-arm, double-blind, placebo-controlled study in the treatment of acute mania/hypomania.
- Conditions
- Bipolar Disorder, Mania, Schizoaffective Disorder
- Trial name
- NCT00206544
- Testing
- Tamoxifen, Progesterone
- Where
- Australia
- Volunteers
- 51 people
- Sponsor
- The Alfred
Schizophrenia, Substance Use Disorders
The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients
The lifetime of substance use disorders in schizophrenia is close to 50%. Substance abuse in schizophrenia is associated with negative consequences.
- Trial name
- NCT00295412
- Testing
- quetiapine (drug)
- Where
- Canada
- Sponsor
- Université de Montréal
Schizophenia Disorder, Schizoaffective Disorder
Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders
The goal of this study is to reduce Anticholinergic Medication (ACM) in persons with psychoses or serious mental illness, when these medications are no longer needed.
- Conditions
- Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder, Psychiatric Disorders
- Trial name
- RAMP (NCT07043803)
- Testing
- Reduction of anticholinergic medication
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Schizoaffective Disorder
Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs
Background: Antipsychotics can induce metabolic disorders such as obesity, hyperglycemia, dyslipidemia or metabolic syndrome. It has been observed that treatment with antipsychotic could be accompanied by a decrease in the…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT02986490
- Testing
- Blood sample
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Montpellier
Schizophrenia, Bipolar Disorder
Longitudinal Effect of Electroconvulsive Therapy on Schizophrenia and Bipolar Disorder: a MRI Study
For more severe and treatment-resistant cases in schizophrenia and bipolar disorder, electroconvulsive therapy (ECT) is often very effective.
- Trial name
- NCT03651674
- Testing
- ECT treatment, Drug treatment
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Xidian University
Schizophrenia and Related Disorders
Individualized Repetitive Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations
The Repetitive Transcranial Magnetic Stimulation (rTMS) is a type of brain stimulation that uses a magnet to change activity in the brain.
- Trial name
- NCT05319080
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Columbia University
Major Depression, Schizophrenia
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Individuals with severe mental illness (SMI) including schizophrenia and bipolar disorder are dying younger than the general population; cancer is a leading cause of death in this population.
- Conditions
- Major Depression, Schizophrenia, Bipolar Disorder, Lung Cancer
- Trial name
- NCT02594696
- Testing
- Proactive Psychiatry Consultation (PPC)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Massachusetts General Hospital